

## Special Issue

# Novel Non-antibiotics Approaches for One Health Sustainability

### Message from the Guest Editors

The development of vaccines to fight infectious diseases represents a cornerstone in sustaining animal and human health. In this era of antibiotic crisis, the development of non-antibiotic strategies to curtail infectious diseases in animals represents a great triumph for the One Health concept. We aim to achieve a more comprehensive understanding of the scientific knowledge and current trends in the Perspectives and Novel Non-Antibiotics Approaches for One Health Sustainability. Therefore, we are pleased to invite you to contribute high-quality original research articles, reviews and communications on the latest progress in: (i) the development of novel prophylactic and therapeutic vaccines and adjuvants; (ii) the identification of target protective antigens; (iii) novel immunotherapy strategies; (iv) clinical trials on the effectiveness and/or safety of animal and human vaccines; (v) the immunopathogenesis of and protective immunity against infectious diseases in animals and humans; (vi) the immune response to vaccines; and (vii) novel non-antibiotic (immunological) approaches to fighting infectious diseases.

---

### Guest Editors

Dr. Fernando Nogueira De Souza

Dr. Marcos Bryan Heinemann

Dr. Paulo Bettencourt

---

### Deadline for manuscript submissions

closed (31 December 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/155152](https://mdpi.com/si/155152)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).